Cargando…
HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China
BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271504/ https://www.ncbi.nlm.nih.gov/pubmed/25510523 http://dx.doi.org/10.1186/s12879-014-0689-7 |
_version_ | 1782349618598641664 |
---|---|
author | Jiao, Yang Li, Shuming Li, Zhenpeng Zhang, Zheng Zhao, Jianhong Li, Li Wang, Lijuan Yin, Qianqian Wang, Yan Zeng, Zhaoli Shao, Yiming Ma, Liying |
author_facet | Jiao, Yang Li, Shuming Li, Zhenpeng Zhang, Zheng Zhao, Jianhong Li, Li Wang, Lijuan Yin, Qianqian Wang, Yan Zeng, Zhaoli Shao, Yiming Ma, Liying |
author_sort | Jiao, Yang |
collection | PubMed |
description | BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports are scarce on HIV TDR-associated mutations and their co-variation among MSM. METHODS: Blood samples from 262 newly diagnosed HIV-positive, antiretroviral therapy (ART)-naïve MSM, were collected from January 2011 and December 2013 in Beijing. The polymerase viral genes were sequenced to explore TDR-associated mutations and mutation co-variation. RESULTS: A total of 223 samples were sequenced and analyzed. Among them, HIV-1 CRF01_AE are accounted for 60.5%, followed by CRF07_BC (27.8%), subtype B (9.9%), and others. Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year. Moreover, eight significant co-variation pairs were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype CRF01_AE. CONCLUSIONS: To date, this work consists the most comprehensive genetic characterization of HIV-1 TDR-associated mutations prevalent among MSM. It provides important information for understanding TDR and viral evolution among Chinese MSM, a population currently at particularly high risk of HIV transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0689-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4271504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42715042014-12-20 HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China Jiao, Yang Li, Shuming Li, Zhenpeng Zhang, Zheng Zhao, Jianhong Li, Li Wang, Lijuan Yin, Qianqian Wang, Yan Zeng, Zhaoli Shao, Yiming Ma, Liying BMC Infect Dis Research Article BACKGROUND: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men (MSM) constitute a major risk group for HIV transmission. However, current reports are scarce on HIV TDR-associated mutations and their co-variation among MSM. METHODS: Blood samples from 262 newly diagnosed HIV-positive, antiretroviral therapy (ART)-naïve MSM, were collected from January 2011 and December 2013 in Beijing. The polymerase viral genes were sequenced to explore TDR-associated mutations and mutation co-variation. RESULTS: A total of 223 samples were sequenced and analyzed. Among them, HIV-1 CRF01_AE are accounted for 60.5%, followed by CRF07_BC (27.8%), subtype B (9.9%), and others. Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year. Moreover, eight significant co-variation pairs were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype CRF01_AE. CONCLUSIONS: To date, this work consists the most comprehensive genetic characterization of HIV-1 TDR-associated mutations prevalent among MSM. It provides important information for understanding TDR and viral evolution among Chinese MSM, a population currently at particularly high risk of HIV transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0689-7) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-16 /pmc/articles/PMC4271504/ /pubmed/25510523 http://dx.doi.org/10.1186/s12879-014-0689-7 Text en © Jiao et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Jiao, Yang Li, Shuming Li, Zhenpeng Zhang, Zheng Zhao, Jianhong Li, Li Wang, Lijuan Yin, Qianqian Wang, Yan Zeng, Zhaoli Shao, Yiming Ma, Liying HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title | HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title_full | HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title_fullStr | HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title_full_unstemmed | HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title_short | HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China |
title_sort | hiv-1 transmitted drug resistance-associated mutations and mutation co-variation in hiv-1 treatment-naïve msm from 2011 to 2013 in beijing, china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271504/ https://www.ncbi.nlm.nih.gov/pubmed/25510523 http://dx.doi.org/10.1186/s12879-014-0689-7 |
work_keys_str_mv | AT jiaoyang hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT lishuming hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT lizhenpeng hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT zhangzheng hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT zhaojianhong hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT lili hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT wanglijuan hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT yinqianqian hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT wangyan hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT zengzhaoli hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT shaoyiming hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina AT maliying hiv1transmitteddrugresistanceassociatedmutationsandmutationcovariationinhiv1treatmentnaivemsmfrom2011to2013inbeijingchina |